KNSA Share Price Performance
US$33.07
8.79 (36.20%)
26.8% undervalued intrinsic discount
US$45.17
Fair Value
Price US$33.07
AnalystConsensusTarget US$45.17
Fair ValueUS$45.17
Share PriceUS$33.07
26.8% undervalued intrinsic discount
KNSA Community Narratives
AN
Fair Value US$45.17 26.8% undervalued intrinsic discount
Medicare Part D And KPL-387 Trials Will Shape Future Success
0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
KNSA Community Fair Values
- US$45.17FV26.8% undervalued intrinsic discount23.50%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative16users have followed this narrativeUpdated narrative
Recent KNSA News & Updates
No updates
Kiniksa Pharmaceuticals International, plc Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.065
- Gross Margin
- 53.11%
- Net Profit Margin
- 0.90%
- Debt/Equity Ratio
- 0%
Kiniksa Pharmaceuticals International, plc Competitors
About KNSA
- Founded
- 2015
- Employees
- 315
- CEO
- WebsiteView website
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
U.K. Market Performance
- 7 Days: 0.3%
- 3 Months: 18.2%
- 1 Year: 16.0%
- Year to Date: 14.9%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. As for the longer term, the market has risen 16% in the past 12 months. Looking forward, earnings are forecast to grow by 13% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading